> top > docs > PMC:7228307 > spans > 53105-53798 > annotations

PMC:7228307 / 53105-53798 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id tao:has_standard_notation
1088 77-82 Gene denotes FcγRI Gene:2214
1089 87-94 Gene denotes FcγRIIb Gene:2213
1090 350-354 Gene denotes FcγR Gene:2213
1091 149-153 Gene denotes FcγR Gene:2213
1092 652-656 Gene denotes FcγR Gene:2213
1093 474-484 Chemical denotes disulfides MESH:D004220
1094 110-136 Disease denotes PD‐1 antibody tislelizumab MESH:D010300
1095 265-270 Mutation denotes E233P p.E233P
1096 272-277 Mutation denotes F234V rs755807976
1097 279-284 Mutation denotes L235A p.L235A
1098 312-317 Mutation denotes D265A p.D265A
1099 415-420 Mutation denotes S228P rs1469294455
1100 433-438 Mutation denotes L309V p.L309V
1101 443-448 Mutation denotes R409K p.R409K

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T409 115-123 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T410 545-547 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T896 77-79 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T897 87-89 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T898 137-140 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T899 149-151 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T900 202-206 http://purl.obolibrary.org/obo/CLO_0007179 denotes L235
T901 262-263 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T902 342-343 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T903 350-352 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T904 379-382 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T905 630-631 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T906 652-654 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T907 680-690 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T28 80-82 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T85014 110-112 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T2607 474-484 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T59 474-484 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes pubann:has_HGVS_notation
1088 77-82 Gene denotes FcγRI Gene:2214
1089 87-94 Gene denotes FcγRIIb Gene:2213
1090 350-354 Gene denotes FcγR Gene:2213
1091 149-153 Gene denotes FcγR Gene:2213
1092 652-656 Gene denotes FcγR Gene:2213
1093 474-484 Chemical denotes disulfides MESH:D004220
1094 110-136 Disease denotes PD‐1 antibody tislelizumab MESH:D010300
1095 265-270 Mutation denotes E233P p.E233P
1096 272-277 Mutation denotes F234V rs755807976
1097 279-284 Mutation denotes L235A p.L235A
1098 312-317 Mutation denotes D265A p.D265A
1099 415-420 Mutation denotes S228P rs1469294455
1100 433-438 Mutation denotes L309V p.L309V
1101 443-448 Mutation denotes R409K p.R409K

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T302 0-95 Sentence denotes IgG4 mAbs have been similarly engineered to eliminate their interaction with FcγRI and FcγRIIb.
T303 96-370 Sentence denotes The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2.
T304 371-588 Sentence denotes It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4.
T305 589-693 Sentence denotes Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T715 110-114 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T408 115-123 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T409 545-547 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871

LitCovid-sample-PD-GO-BP-0

Id Subject Object Predicate Lexical cue
T122 548-556 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 669-690 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation

LitCovid-sample-GO-BP

Id Subject Object Predicate Lexical cue
T122 548-556 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 669-690 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T122 548-556 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 669-690 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T302 0-95 Sentence denotes IgG4 mAbs have been similarly engineered to eliminate their interaction with FcγRI and FcγRIIb.
T303 96-370 Sentence denotes The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2.
T304 371-588 Sentence denotes It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4.
T305 589-693 Sentence denotes Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17